|
1
|
Chan AT and Giovannucci EL: Primary
prevention of colorectal cancer. Gastroenterology. 138:2029–2043.
e102010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Half E and Arber N: Colon cancer:
Preventive agents and the present status of chemoprevention. Expert
Opin Pharmacother. 10:211–219. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Fathi M, Taghikhani M, Ghannadi-Maragheh M
and Yavari K: Demonstration of dose dependent cytotoxic activity in
SW480 colon cancer cells by 177Lu-labeled siRNA
targeting IGF-1R. Nucl Med Biol. 40:529–536. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Mésange P, Poindessous V, Sabbah M,
Escargueil AE, De Gramont A and Larsen AK: Intrinsic bevacizumab
resistance is associated with prolonged activation of autocrine
VEGF signaling and hypoxia tolerance in colorectal cancer cells and
can be overcome by nintedanib, a small molecule angiokinase
inhibitor. Oncotarget. 5:4709–4721. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Zhang X, Sun B and Lu Z: Evaluation of
clinical value of single nucleotide polymorphisms of
dihydropyrimidine dehydrogenase gene to predict 5-fluorouracil
toxicity in 60 colorectal cancer patients in China. Int J Med Sci.
10:894–902. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Pan MH, Lai CS, Wu JC and Ho CT: Molecular
mechanisms for chemoprevention of colorectal cancer by natural
dietary compounds. Mol Nutr Food Res. 55:32–45. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Tao YL: Research progress of DPYD gene
variation in colorectal cancer. Zhong Liu Yan Jiu Yu Lin Chuang.
26:206–209. 2014.(In Chinese).
|
|
8
|
Suenaga M, Fuse N, Yamaguchi T, Yamanaka
Y, Motomura S, Matsumoto H, Hamamoto Y, Mizunuma N, Doi T, Hatake
K, et al: Pharmacokinetics, safety, and efficacy of FOLFIRI plus
bevacizumab in Japanese colorectal cancer patients with UGT1A1 gene
polymorphisms. J Clin Pharmacol. 54:495–502. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Rezaei-Tavirani M, Safaei A and Zali MR:
The association between polymorphismsin insulin and obesity related
genesand risk of colorectal cancer. Iran J Cancer Prev. 6:179–185.
2013.PubMed/NCBI
|
|
10
|
Schmidt EF and Strittmatter SM: The CRMP
family of proteins and their role in Sema3A signaling. Adv Exp Med
Biol. 600:1–11. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Alabed YZ, Pool M, Tone S Ong and Fournier
AE: Identification of CRMP4 as a convergent regulator of axon
outgrowth inhibition. J Neurosci. 27:1702–1711. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Alabed YZ, Pool M, Tone S Ong, Sutherland
C and Fournier AE: GSK3 beta regulates myelin-dependent axon
outgrowth inhibition through CRMP4. J Neurosci. 30:5635–5643. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Niisato E, Nagai J, Yamashita N, Abe T,
Kiyonari H, Goshima Y and Ohshima T: CRMP4 suppresses apical
dendrite bifurcation of CA1 pyramidal neurons in the mouse
hippocampus. Dev Neurobiol. 72:1447–1457. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Gao X, Pang J, Li LY, Liu WP, Di JM, Sun
QP, Fang YQ, Liu XP, Pu XY, He D, et al: Expression profiling
identifies new function of collapsin response mediator protein 4 as
a metastasis-suppressor in prostate cancer. Oncogene. 29:4555–4566.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Hiroshima Y, Nakamura F, Miyamoto H, Mori
R, Taniguchi K, Matsuyama R, Akiyama H, Tanaka K, Ichikawa Y, Kato
S, et al: Collapsin response mediator protein 4 expression is
associated with liver metastasis and poor survival in pancreatic
cancer. Ann Surg Oncol. 20(Suppl 3): S369–S378. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Jemal A, Siegel R, Xu J and Ward E: Cancer
statistics, 2010. CA Cancer J Clin. 60:277–300. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Nordlinger B, Sorbye H, Glimelius B,
Poston GJ, Schlag PM, Rougier P, Bechstein WO, Primrose JN, Walpole
ET, Finch-Jones M, et al: Perioperative chemotherapy with FOLFOX4
and surgery versus surgery alone for resectable liver metastases
from colorectal cancer (EORTC Intergroup trial 40983): A randomised
controlled trial. Lancet. 371:1007–1016. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Burnett JC, Rossi JJ and Tiemann K:
Current progress of siRNA/shRNA therapeutics in clinical trials.
Biotechnol J. 6:1130–1146. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ying HQ, Wang F, He BS, Pan YQ, Gao TY, Xu
YQ, Li R, Deng QW, Sun HL and Wang SK: The involvement of Kras gene
3′-UTR polymorphisms in risk of cancer and influence on patient
response to anti-EGFR therapy in metastatic colorectal cancer: A
meta-analysis. Onco Targets Ther. 7:1487–1496. 2014.PubMed/NCBI
|
|
20
|
Quinn CC, Gray GE and Hockfield S: A
family of proteins implicated in axon guidance and outgrowth. J
Neurobiol. 41:158–164. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Li B, Perabekam S, Liu G, Yin M, Song S
and Larson A: Experimental and bioinformatics comparison of gene
expression between T cells from TIL of liver cancer and T cells
from UniGene. J Gastroenterol. 37:275–282. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zhou W, Xie P, Pang M, Yang B, Fang Y, Shu
T, Liu C, Wang X, Zhang L, Li S and Rong L: Upregulation of CRMP4,
a new prostate cancer metastasis suppressor gene, inhibits tumor
growth in a nude mouse intratibial injection model. Int J Oncol.
46:290–298. 2015.PubMed/NCBI
|
|
23
|
Sen GL and Blau HM: A brief history of
RNAi: The silence of the genes. FASEB J. 20:1293–1299. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Lui Z, Ma Q, Wang X and Zhang Y:
Inhibiting tumor growth of colorectal cancer by blocking the
expression of vascular endothelial growth factor receptor 3 using
interference vector-based RNA interference. Int J Mol Med.
25:59–64. 2010.PubMed/NCBI
|
|
25
|
Ghildiyal M and Zamore PD: Small silencing
RNAs: An expanding universe. Nat Rev Genet. 10:94–108. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Kim VN, Han J and Siomi MC: Biogenesis of
small RNAs in animals. Nat Rev Mol Cell Biol. 10:126–139. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Czech B and Hannon GJ: Small RNA sorting:
Matchmaking for argonautes. Nat Rev Genet. 12:19–31. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Pan SH, Chao YC, Chen HY, Hung PF, Lin PY,
Lin CW, Chang YL, Wu CT, Lee YC, Yang SC, et al: Long form
collapsin response mediator protein-1 (LCRMP-1) expression is
associated with clinical outcome and lymph node metastasis in
non-small cell lung cancer patients. Lung Cancer. 67:93–100. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Shih JY, Yang SC, Hong TM, Yuan A, Chen
JJ, Yu CJ, Chang YL, Lee YC, Peck K, Wu CW and Yang PC: Collapsin
response mediator protein-1 and the invasion and metastasis of
cancer cells. J Natl Cancer Inst. 93:1392–1400. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Wu CC, Chen HC, Chen SJ, Liu HP, Hsieh YY,
Yu CJ, Tang R, Hsieh LL, Yu JS and Chang YS: Identification of
collapsin response mediator protein-2 as a potential marker of
colorectal carcinoma by comparative analysis of cancer cell
secretomes. Proteomics. 8:316–332. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Vincent P, Collette Y, Marignier R,
Vuaillat C, Rogemond V, Davoust N, Malcus C, Cavagna S, Gessain A,
Machuca-Gayet I, et al: A role for the neuronal protein collapsin
response mediator protein 2 in T lymphocyte polarization and
migration. J Immunol. 175:7650–7660. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Llanos S, Efeyan A, Monsech J, Dominguez O
and Serrano M: A high-throughput loss-of-function screening
identifies novel p53 regulators. Cell Cycle. 5:1880–1885. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Castellani V, Falk J and Rougon G:
Semaphorin3A-induced receptor endocytosis during axon guidance
responses is mediated by L1 CAM. Mol Cell Neurosci. 26:89–100.
2004. View Article : Google Scholar : PubMed/NCBI
|
